---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-138214"
form_type: "8-K"
ticker: null
cik: "0001604950"
company_name: "scPharmaceuticals Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:50:57.868321+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# scPharma Q1 net loss $14.1M; FUROSCIX revenue $6.1M, doses written up 28% QoQ

## Summary
- Net FUROSCIX revenue $6.1M vs $2.1M in Q1 2023; gross-to-net discount 19%.
- Net loss $14.1M vs $11.2M; cash and equivalents $58.4M at quarter end.
- 17,376 doses written (+28% QoQ); 8,074 filled (+15% QoQ); 2,938 in-services completed.
- Change Healthcare cyberattack estimated 10% negative impact on doses filled in Q1.
- FDA PDUFA date August 2024 for Class IV HF indication; PK study for auto-injector underway.

## SEC filing metadata
- accession: 0001193125-24-138214
- form_type: 8-K
- cik: 0001604950
- company_name: scPharmaceuticals Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/0001193125-24-138214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/d810552d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-138214
- JSON: https://secwatch.observer/filing/0001193125-24-138214.json
- Plain text: https://secwatch.observer/filing/0001193125-24-138214.txt

## Key facts
- Earnings Releases
  scPharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $6.1 million, net income $14.1 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $6.1 million
  - Net income: $14.1 million
  - Result: reported results
  source text: (EX-99.1) --- EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/0001193125-24-138214-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.